Matt Zeller, country president of Novartis Australia and New Zealand, said, “The impact of CVD in Australia is devastating, claiming one life every 12 minutes. Now, Leqvio is available on the PBS and this first-in-class treatment option has the potential to transform patient care and help improve the lives of individuals living with CVD.”
Novartis welcomes the listing of first-in-class cholesterol-lowering therapy
April 2, 2024 Latest NewsBioPharmaLatest Video
New Stories
-
Moderna Announces the awardees for its 2024 Australia Fellowship Program
November 11, 2024 - - Latest News -
Mark Butler announces the creation of hybrid national program for RSV vaccine
November 11, 2024 - - Latest News -
Patients win when health ministers do what they are elected to do
November 11, 2024 - - Latest News -
Pharmac makes cancer therapy the 26th funded since budget boost
November 11, 2024 - - BioPharma -
Lundbeck announces its new leadership for Australia and NZ
November 8, 2024 - - Latest News -
ACCC will not oppose Sigma-Chemist Warehouse merger, subject to undertaking
November 8, 2024 - - Latest News -
AusBiotech and MTPConnect launch joint discussion paper on life science growth issues
November 8, 2024 - - Latest News